Mirion Q1 2026: RPO Stable but Nuclear Order Proof Still Needed

What happened

Mirion's Q1 2026 earnings call reported revenue and adjusted EBITDA within guided ranges, but the key remaining performance obligations (RPO) remained stable near $1.1 billion. Management reaffirmed full-year 2026 adjusted EBITDA of $285–300 million and FCF of $155–175 million, but organic growth stayed within the 5–7% range. No major new large opportunity pipeline awards were disclosed, leaving the sustainability of order momentum unconfirmed. Paragon integration contributed revenue but no incremental disclosed project wins beyond acquired backlog. With EV/EBITDA above 28x and net leverage at 4.0x, the stock is priced for high execution yet Q1 offered no catalyst for further multiple expansion.

Implication

Q1 earnings call provided no incremental catalyst to alter the thesis. RPO stability is positive but insufficient to justify current multiples; the market needs clear organic order acceleration, especially from large opportunity pipeline wins, to re-rate. For long-term investors, risk/reward is unattractive above $21; attractive entry near $19. Monitor Q2 for upward guidance revision or disclosed large awards. Absent those, the stock may drift lower as high expectations fail to materialize.

Thesis delta

No material shift in thesis from Q1 2026 earnings. The call reaffirmed guidance and showed RPO stability but failed to deliver the fresh large-order proof needed to sustain the nuclear momentum narrative. The base case remains intact, but the bull case requires faster order conversion and larger disclosed wins than Q1 demonstrated. The bear case risk of schedule slippage persists, and the stock offers no upside without clear operational acceleration.